TLR9 and breast cancer: van Pul et al. reported that in vitro immunomodulation of Toll-like receptor-9 agonist CpG-B on SLN can effectively overcome immunosuppression by preferentially activating lymph node-resident dendritic cells to restore antitumor immunity, thereby ensuring breast cancer-specific T cell response [32].